<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31810920</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss of MDC1 in Endometrial Carcinoma Is Associated With Loss of MRN Complex and MMR Deficiency.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6547-6553</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13870</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the frequency of loss of mediator of DNA damage checkpoint protein 1 (MDC1) protein expression in endometrial cancer (EC) and to determine whether loss of MDC1 is associated with certain clinicopathological parameters.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">MDC1 expression was examined in 426 samples of EC. The nuclear immunoreactivity of the protein was defined as: negative, weak, moderate and strong.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Loss of MDC1 expression (defined as negative nuclear staining) was found in 8.9% (38/426) of ECs and was significantly associated with the loss of MRE11 homolog, double-strand break repair nuclease, RAD50 double-strand break repair protein and nibrin complex components. In addition, loss of expression of MDC1 showed a significant correlation with any mismatch repair deficiency, with endometrioid histological subtype and low tumour grading.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on these findings, we suggest that MDC1 loss frequently occurs in ECs with microsatellite instability. Due to deficient homologous recombination DNA repair, MDC1-negative ECs might show an increased sensitivity to poly(ADP-ribose) polymerase-inhibitory therapy.</AbstractText>
                <CopyrightInformation>CopyrightÂ© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Merentitis</LastName>
                    <ForeName>Danae</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecologic Oncology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Bich Doan</ForeName>
                    <Initials>BD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecologic Oncology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samartzis</LastName>
                    <ForeName>Eleftherios P</ForeName>
                    <Initials>EP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecologic Oncology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noske</LastName>
                    <ForeName>Aurelia</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brandt</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dedes</LastName>
                    <ForeName>Konstantin J</ForeName>
                    <Initials>KJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecologic Oncology, University Hospital of Zurich, Zurich, Switzerland konstantin.dedes@usz.ch.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C413163">MDC1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C112156">NBN protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.-</RegistryNumber>
                <NameOfSubstance UI="D000076228">MRE11 Homologue Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.-</RegistryNumber>
                <NameOfSubstance UI="C112158">Rad50 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 6.5.1.-</RegistryNumber>
                <NameOfSubstance UI="D045643">DNA Repair Enzymes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053843" MajorTopicYN="N">DNA Mismatch Repair</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045643" MajorTopicYN="N">DNA Repair Enzymes</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000076228" MajorTopicYN="N">MRE11 Homologue Protein</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D046888" MajorTopicYN="N">Tissue Array Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MDC1</Keyword>
            <Keyword MajorTopicYN="N">PARP</Keyword>
            <Keyword MajorTopicYN="N">endometrial carcinoma</Keyword>
            <Keyword MajorTopicYN="N">mismatch repair</Keyword>
            <Keyword MajorTopicYN="N">targeted therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31810920</ArticleId>
            <ArticleId IdType="pii">39/12/6547</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13870</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31810907</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6431-6441</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13857</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">About 15-20% of colorectal cancers (CRCs) have deficiency in a mismatch repair (MMR) protein. MMR has a high level of microsatellite instability (MSI-H). We have conducted this review and meta-analysis to determine the prognostic role of MSI-H status in stage II CRC.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We searched PubMed, EMBASE, The Cochrane Library, Web of Science, and SCOPUS for studies reporting data on overall survival (OS) and disease-free or relapse-free survival (DFS or RFS) for MSI-H compared to microsatellite stable (MSS) CRC.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 39 studies were analysed, including 12,110 patients. MSI-H status was associated with a significantly reduced risk of death (HR=0.64, 95%CI=0.52-0.8, p&lt;0.01) and relapse (HR=0.59, 95%CI=0.45-0.77, p&lt;0.01) in stage II CRC.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MSI-H represents an important prognostic determinant in stage II CRC and may be considered when estimating the risk of recurrence in stage II CRC.</AbstractText>
                <CopyrightInformation>CopyrightÂ© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Petrelli</LastName>
                    <ForeName>Fausto</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy faupe@libero.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghidini</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cabiddu</LastName>
                    <ForeName>Mary</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pezzica</LastName>
                    <ForeName>Ezio</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corti</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Turati</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Surgical Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Costanzo</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Surgical Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varricchio</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Surgical Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghidini</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Casa di Cura Igea, Oncology Unit, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barni</LastName>
                    <ForeName>Sandro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomasello</LastName>
                    <ForeName>Gianluca</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053843" MajorTopicYN="N">DNA Mismatch Repair</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">meta-analysis</Keyword>
            <Keyword MajorTopicYN="N">microsatellite instability</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
            <Keyword MajorTopicYN="N">review</Keyword>
            <Keyword MajorTopicYN="N">stage II</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31810907</ArticleId>
            <ArticleId IdType="pii">39/12/6431</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13857</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31807843</PMID>
        <DateCompleted>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1432-1963</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>Suppl 3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Der Pathologe</Title>
                <ISOAbbreviation>Pathologe</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Importance of tumour mutation burden testing].</ArticleTitle>
            <Pagination>
                <MedlinePgn>366-368</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00292-019-00717-3</ELocationID>
            <Abstract>
                <AbstractText>Although therapy with immune checkpoint inhibitors (ICIs) for patients with non-small-cell lung carcinoma (NSCLC), which has recently become available, does offer a survival advantage compared with chemotherapy, the overall response rate is only around 20â¯%. Biomarkers are increasingly important in identifying patients who would benefit from ICI therapy. Expression of PD-L1 was the first predictive biomarker to be developed, but was unable to sufficiently predict the efficacy of ICI. Another biomarker, tumour mutation burden (TMB), is defined as the number of mutations per megabase of DNA analysed. Microsatellite instability also acts as a predictive marker for ICI therapy response. Many tumour entities demonstrate a high correlation between MSI and high TMB. Studies show a benefit of progression-free survival for patients with NSCLC and a TMB of at least 10 mutations per megabase.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wild</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dr. Senckenbergisches Institut fÃ¼r Pathologie, UniversitÃ¤tsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland. peter.wild@kgu.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Stellenwert der Testung der Tumormutationslast.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Pathologe</MedlineTA>
            <NlmUniqueID>8006541</NlmUniqueID>
            <ISSNLinking>0172-8113</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DNA sequence analysis</Keyword>
            <Keyword MajorTopicYN="N">Monoclonal antibodies</Keyword>
            <Keyword MajorTopicYN="N">NSCLC</Keyword>
            <Keyword MajorTopicYN="N">Non-small-cell lung carcinoma</Keyword>
            <Keyword MajorTopicYN="N">TMB</Keyword>
            <Keyword MajorTopicYN="N">Tumor burden</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31807843</ArticleId>
            <ArticleId IdType="doi">10.1007/s00292-019-00717-3</ArticleId>
            <ArticleId IdType="pii">10.1007/s00292-019-00717-3</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2015 Apr 3;348(6230):124-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25765070</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2019 Apr 20;37(12):992-1000</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30785829</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Med. 2017 Apr 19;9(1):34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28420421</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2019 May 1;144(9):2303-2312</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30446996</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2018 May 31;378(22):2093-2104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29658845</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2017 Jun 22;376(25):2415-2426</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28636851</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31768066</PMID>
        <DateCompleted>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-170X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature medicine</Title>
                <ISOAbbreviation>Nat. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1928-1937</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-019-0652-7</ELocationID>
            <Abstract>
                <AbstractText>Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. We sought to define the technical feasibility of a high-intensity sequencing assay of cfDNA and matched white blood cell DNA covering a large genomic region (508 genes; 2âmegabases; &gt;60,000Ã raw depth) in a prospective study of 124 patients with metastatic cancer, with contemporaneous matched tumor tissue biopsies, and 47 controls without cancer. The assay displayed high sensitivity and specificity, allowing for de novo detection of tumor-derived mutations and inference of tumor mutational burden, microsatellite instability, mutational signatures and sources of somatic mutations identified in cfDNA. The vast majority of cfDNA mutations (81.6% in controls and 53.2% in patients with cancer) had features consistent with clonal hematopoiesis. This cfDNA sequencing approach revealed that clonal hematopoiesis constitutes a pervasive biological phenomenon, emphasizing the importance of matched cfDNA-white blood cell sequencing for accurate variant interpretation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Razavi</LastName>
                    <ForeName>Pedram</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4236-0576</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. razavip@mskcc.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. razavip@mskcc.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Bob T</ForeName>
                    <Initials>BT</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6661-8733</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>David N</ForeName>
                    <Initials>DN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Byoungsok</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hubbell</LastName>
                    <ForeName>Earl</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Ronglai</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abida</LastName>
                    <ForeName>Wassim</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Juluru</LastName>
                    <ForeName>Krishna</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8203-8894</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Bruijn</LastName>
                    <ForeName>Ino</ForeName>
                    <Initials>I</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5427-4750</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Marie-JosÃ©e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Chenlu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Venn</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Raymond</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anand</LastName>
                    <ForeName>Aseem</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maddala</LastName>
                    <ForeName>Tara</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gnerre</LastName>
                    <ForeName>Sante</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vijaya Satya</LastName>
                    <ForeName>Ravi</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Qinwen</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eattock</LastName>
                    <ForeName>Nicholas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yue</LastName>
                    <ForeName>Jeanne</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blocker</LastName>
                    <ForeName>Alexander W</ForeName>
                    <Initials>AW</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7486-9919</Identifier>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Foresite Capital Management, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Genentech, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sehnert</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>MyoKardia, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hall</LastName>
                    <ForeName>Megan P</ForeName>
                    <Initials>MP</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7300-5027</Identifier>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santiago-Zayas</LastName>
                    <ForeName>Angie</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Novotny</LastName>
                    <ForeName>William F</ForeName>
                    <Initials>WF</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>BeiGene, San Mateo, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isbell</LastName>
                    <ForeName>James M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rusch</LastName>
                    <ForeName>Valerie W</ForeName>
                    <Initials>VW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plitas</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heerdt</LastName>
                    <ForeName>Alexandra S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ladanyi</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyman</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8150-9762</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morrow</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4636-8313</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riely</LastName>
                    <ForeName>Gregory J</ForeName>
                    <Initials>GJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scher</LastName>
                    <ForeName>Howard I</ForeName>
                    <Initials>HI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rudin</LastName>
                    <ForeName>Charles M</ForeName>
                    <Initials>CM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5204-3465</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robson</LastName>
                    <ForeName>Mark E</ForeName>
                    <Initials>ME</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3109-1692</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diaz</LastName>
                    <ForeName>Luis A</ForeName>
                    <Initials>LA</Initials>
                    <Suffix>Jr</Suffix>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7079-8914</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Solit</LastName>
                    <ForeName>David B</ForeName>
                    <Initials>DB</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6614-802X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Marie-JosÃ©e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aravanis</LastName>
                    <ForeName>Alexander M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>GRAIL, Inc., Menlo Park, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reis-Filho</LastName>
                    <ForeName>Jorge S</ForeName>
                    <Initials>JS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2969-3173</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reisfilj@mskcc.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reisfilj@mskcc.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA008748</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA234361</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Med</MedlineTA>
            <NlmUniqueID>9502015</NlmUniqueID>
            <ISSNLinking>1078-8956</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000073888">Cell-Free Nucleic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Ann Transl Med. 2019 Dec;7(Suppl 8):S384</RefSource>
                <PMID Version="1">32016102</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073888" MajorTopicYN="N">Cell-Free Nucleic Acids</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000074141" MajorTopicYN="N">Circulating Tumor DNA</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31768066</ArticleId>
            <ArticleId IdType="doi">10.1038/s41591-019-0652-7</ArticleId>
            <ArticleId IdType="pii">10.1038/s41591-019-0652-7</ArticleId>
            <ArticleId IdType="pmc">PMC7061455</ArticleId>
            <ArticleId IdType="mid">NIHMS1541314</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nucleic Acids Res. 2016 Sep 19;44(16):e131</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27270079</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2013 Mar 28;368(13):1199-209</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23484797</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2017 Jun 1;376(22):2109-2121</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28445112</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 1977 Mar;37(3):646-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">837366</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2017 Feb 9;168(4):571-574</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28187279</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Commun. 2016 Jun 10;7:11815</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27283993</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Stem Cell. 2018 Feb 1;22(2):157-170</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29395053</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Transl Med. 2014 Feb 19;6(224):224ra24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24553385</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Transl Med. 2017 Aug 16;9(403):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28814544</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2017 Jul 13;377(2):111-121</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28636844</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2014 Dec;20(12):1472-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25326804</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Stem Cells. 2018 Sep;36(9):1287-1294</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29883022</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2018 Jun 1;24(11):2688-2699</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29463554</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Discov. 2018 Feb;8(2):174-183</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29247016</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Dec 25;371(26):2477-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25426838</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19096-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19861545</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28803919</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Sep 15;23(18):5648-5656</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28536309</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Biotechnol. 2012 May;30(5):413-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22544022</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Commun. 2016 Aug 22;7:12484</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27546487</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Commun. 2017 Nov 6;8(1):1324</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29109393</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2013 May 2;497(7447):108-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23563269</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2015 Jun 25;372(26):2509-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26028255</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2018 Feb 23;359(6378):926-930</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29348365</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA Oncol. 2016 Aug 1;2(8):1014-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27055085</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JCO Precis Oncol. 2017 Jul;2017:</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28890946</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Blood. 2017 Aug 10;130(6):742-752</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28483762</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21586637</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2014 Feb 20;32(6):579-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24449238</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Hum Genet. 2017 Jul 6;101(1):50-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28669404</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2015 Oct 16;10(10):e0140712</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26474073</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2017 Jun;23(6):703-713</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28481359</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2016 May 02;534(7605):47-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27135926</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29504834</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS Genet. 2018 Jan 4;14(1):e1007108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29300727</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2016 Aug 17;536(7616):285-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27535533</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2016 Feb 01;108(6):djv427</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26832770</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2018 Apr 1;29(4):1049-1055</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29325035</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2018 Sep 15;24(18):4437-4443</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29567812</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur Urol. 2012 Jul;62(1):78-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22306323</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Cancer Clin Oncol. 1987 Jun;23(6):707-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3653190</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA Oncol. 2018 Jul 1;4(7):944-951</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29799999</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2013 Oct 17;502(7471):333-339</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24132290</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2013 Aug 22;500(7463):415-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23945592</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2017 Oct;49(10):1476-1486</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28825726</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2017 Apr;17(4):223-238</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28233803</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2013 Sep 15;29(18):2238-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23884480</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Biotechnol. 2016 May;34(5):547-555</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27018799</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2016 Dec 1;22(23):5772-5782</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27601595</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Dec 25;371(26):2488-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25426837</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2017 Jan;18(1):112-121</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27927582</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2014 Oct 10;346(6206):251-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25301630</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Biol. 2016 Feb 22;17:31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26899170</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2014 Apr 1;30(7):1015-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24371154</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Mol Diagn. 2015 May;17(3):251-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25801821</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Blood. 2015 Jul 2;126(1):9-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25931582</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31748536</PMID>
        <DateCompleted>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5251</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-13084-7</ELocationID>
            <Abstract>
                <AbstractText>Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic landscape. With the recent development of novel treatments, accurate stratification strategies are needed. Here we present the whole-genome sequencing (WGS) analysis of fresh-frozen metastatic biopsies from 197 mCRPC patients. Using unsupervised clustering based on genomic features, we define eight distinct genomic clusters. We observe potentially clinically relevant genotypes, including microsatellite instability (MSI), homologous recombination deficiency (HRD) enriched with genomic deletions and BRCA2 aberrations, a tandem duplication genotype associated with CDK12<sup>-/-</sup> and a chromothripsis-enriched subgroup. Our data suggests that stratification on WGS characteristics may improve identification of MSI, CDK12<sup>-/-</sup> and HRD patients. From WGS and ChIP-seq data, we show the potential relevance of recurrent alterations in non-coding regions identified with WGS and highlight the central role of AR signaling in tumor progression. These data underline the potential value of using WGS to accurately stratify mCRPC patients into clinically actionable subgroups.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van Dessel</LastName>
                    <ForeName>Lisanne F</ForeName>
                    <Initials>LF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Riet</LastName>
                    <ForeName>Job</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smits</LastName>
                    <ForeName>Minke</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Yanyun</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division on Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Oncode Institute, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamberg</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Franciscus Gasthuis &amp; Vlietland, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Heijden</LastName>
                    <ForeName>Michiel S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bergman</LastName>
                    <ForeName>Andries M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division on Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Oort</LastName>
                    <ForeName>Inge M</ForeName>
                    <Initials>IM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Wit</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voest</LastName>
                    <ForeName>Emile E</ForeName>
                    <Initials>EE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncode Institute, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steeghs</LastName>
                    <ForeName>Neeltje</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Takafumi N</ForeName>
                    <Initials>TN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Livingstone</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0002-8424-3768</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boutros</LastName>
                    <ForeName>Paul C</ForeName>
                    <Initials>PC</Initials>
                    <Identifier Source="ORCID">0000-0003-0553-7520</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biophysics, University of Toronto, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, University of California Los Angeles, Los Angeles, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of California Los Angeles, Los Angeles, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jonsson Comprehensive Cancer Centre, University of California Los Angeles, Los Angeles, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martens</LastName>
                    <ForeName>John W M</ForeName>
                    <Initials>JWM</Initials>
                    <Identifier Source="ORCID">0000-0002-3428-3366</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sleijfer</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cuppen</LastName>
                    <ForeName>Edwin</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Hartwig Medical Foundation, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zwart</LastName>
                    <ForeName>Wilbert</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division on Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Oncode Institute, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van de Werken</LastName>
                    <ForeName>Harmen J G</ForeName>
                    <Initials>HJG</Initials>
                    <Identifier Source="ORCID">0000-0002-9794-1477</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehra</LastName>
                    <ForeName>Niven</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">0000-0002-4794-1831</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lolkema</LastName>
                    <ForeName>Martijn P</ForeName>
                    <Initials>MP</Initials>
                    <Identifier Source="ORCID">0000-0003-0466-2928</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. m.lolkema@erasmusmc.nl.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Personalized Cancer Treatment, Rotterdam, The Netherlands. m.lolkema@erasmusmc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D024682">BRCA2 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C551750">BRCA2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C515553">TMPRSS2-ERG fusion protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="C447339">CDK12 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D024682" MajorTopicYN="N">BRCA2 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000081204" MajorTopicYN="N">Chromatin Immunoprecipitation Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056915" MajorTopicYN="N">DNA Copy Number Variations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004742" MajorTopicYN="N">Enhancer Elements, Genetic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015514" MajorTopicYN="N">Oncogene Proteins, Fusion</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059767" MajorTopicYN="N">Recombinational DNA Repair</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012983" MajorTopicYN="N">Soft Tissue Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31748536</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-019-13084-7</ArticleId>
            <ArticleId IdType="pii">10.1038/s41467-019-13084-7</ArticleId>
            <ArticleId IdType="pmc">PMC6868175</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2015 May 21;161(5):1215-1228</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26000489</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2012 Sep 15;28(18):i333-i339</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22962449</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2009 Jul 15;25(14):1754-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19451168</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Treat Rev. 2017 Mar;54:68-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28231559</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Urol. 2012 Nov;9(11):652-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23132303</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2018 Jul 26;174(3):758-769.e9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30033370</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2017 Jan 19;541(7637):359-364</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28068672</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2015 Apr 3;348(6230):124-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25765070</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Biol. 2011;12(4):R41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21527027</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2017 Oct 1;33(19):3088-3090</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28575171</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neoplasia. 2014 Nov 20;16(11):900-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25425964</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2018 Jun 14;173(7):1770-1782.e14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29906450</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Res. 2014 Nov;24(11):1881-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25060187</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2006 Aug 15;22(16):1963-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16787969</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2017 Sep 15;77(18):4755-4762</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28904067</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2016 May 02;534(7605):47-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27135926</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2018 Aug 1;29(8):1807-1813</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29992241</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Bioinformatics. 2010 Jul 02;11:367</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20598126</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Aug 1;19(15):4058-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23704282</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2016 Aug 17;536(7616):285-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27535533</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Biol Ther. 2007 Jan;6(1):40-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17172822</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncogene. 2018 Jan 18;37(3):313-322</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28925401</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2018 Jul;19(7):975-986</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29880291</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2017 Jan 31;49(2):170-174</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28138153</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2018 May 3;173(4):1003-1013.e15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29681457</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nucleic Acids Res. 2018 Jan 4;46(D1):D762-D769</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29106570</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Biol. 2008;9(9):R137</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18798982</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2014 Sep 15;5(17):7217-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25277175</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Commun. 2014 Sep 25;5:4988</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25255306</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Res. 2012 Sep;22(9):1760-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22955987</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2017 Dec 21;377(25):2500-2501</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29262275</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27899578</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2019 Jan 1;30(1):44-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30395155</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Med. 2018 Apr 25;10(1):33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29695279</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur Urol. 2017 Feb;71(2):183-192</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27451135</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2018 May;50(5):645-651</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29610475</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Med. 2018 Mar 28;10(1):25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29592813</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Biotechnol. 2013 Jul;31(7):615-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23770639</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Cell. 2018 Aug 13;34(2):197-210.e5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30017478</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Commun. 2017 Jan 09;8:13671</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28067867</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2015 Nov 5;163(4):1011-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26544944</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neoplasia. 2008 Feb;10(2):177-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18283340</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Curr Opin Urol. 2016 May;26(3):231-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26909474</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2013 Aug 22;500(7463):415-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23945592</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2017 Oct;49(10):1476-1486</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28825726</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2016 Feb;16(2):110-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26775620</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Genomics. 2013 Apr 08;14:232</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23565824</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2014 Mar 15;74(6):1651-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24473064</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2018 Jul 12;174(2):422-432.e13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29909987</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2019 Feb;51(2):202-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30643254</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2016 Jun 15;122(12):1897-904</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27019001</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2018 Jul 12;174(2):433-447.e19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29909985</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Life Sci Alliance. 2018 Dec 28;2(1):e201800115</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30620009</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2017 Nov 16;171(5):1029-1041.e21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29056346</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2017 Apr;23(4):517-525</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28288110</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31729037</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1427-1435</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.25764</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Mucinous adenocarcinoma is a distinct subtype of colorectal cancer (CRC) with a worse prognosis when compared with non-mucinous adenocarcinoma. The aim of this study was to compare somatic mutations and copy number alteration (CNA) between mucinous and non-mucinous CRC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Data from The Cancer Genome Atlas-colon adenocarcinoma and rectum adenocarcinoma projects were utilized. Mucinous and non-mucinous CRC were compared with regard to microsatellite status, overall mutation rate, the most frequently mutated genes, mutations in genes coding for mismatch repair (MMR) proteins and genes coding for mucin glycoproteins. CNA analysis and pathway analysis was undertaken.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mucinous CRC was more likely to be microsatellite instability-high (MSI-H) and hypermutated. When corrected for microsatellite status the single-nucleotide variation and insertion-deletion rate was similar between the two cohorts. Mucinous adenocarcinoma was more likely to have mutations in genes coding for MMR proteins and mucin glycoproteins. Pathway analysis revealed further differences between the two histological subtypes in the cell cycle, RTK-RAS, transforming growth factor-Î², and TP53 pathways.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mucinous CRC has some distinct genomic aberrations when compared with non-mucinous adenocarcinoma, many of which are driven by the increased frequency of MSI-H tumors. These genomic aberrations may play an important part in the difference seen in response to treatment and prognosis in mucinous adenocarcinoma.</AbstractText>
                <CopyrightInformation>Â© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Reynolds</LastName>
                    <ForeName>Ian S</ForeName>
                    <Initials>IS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8790-2538</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connell</LastName>
                    <ForeName>Emer</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fichtner</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNamara</LastName>
                    <ForeName>Deborah A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kay</LastName>
                    <ForeName>Elaine W</ForeName>
                    <Initials>EW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Beaumont Hospital, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prehn</LastName>
                    <ForeName>Jochen H M</ForeName>
                    <Initials>JHM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furney</LastName>
                    <ForeName>Simon J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Genomic Oncology Research Group, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burke</LastName>
                    <ForeName>John P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>15/ERA-CSM/3268</GrantID>
                    <Agency>Beaumont Hospital Colorectal Research Fund; Science Foundation Ireland</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C094443">G-T mismatch-binding protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009077">Mucins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497796">SMAD4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051901">Smad4 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002288" MajorTopicYN="N">Adenocarcinoma, Mucinous</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056915" MajorTopicYN="N">DNA Copy Number Variations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054643" MajorTopicYN="N">INDEL Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009077" MajorTopicYN="N">Mucins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051901" MajorTopicYN="N">Smad4 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">mucinous adenocarcinoma</Keyword>
            <Keyword MajorTopicYN="N">oncogenetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31729037</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.25764</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>American Cancer Society. Key statistics for colorectal cancer. 2017.</Citation>
            </Reference>
            <Reference>
                <Citation>Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-1356.</Citation>
            </Reference>
            <Reference>
                <Citation>UK Cr. Bowel cancer statistics. 2018.</Citation>
            </Reference>
            <Reference>
                <Citation>Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4:e137-e147.</Citation>
            </Reference>
            <Reference>
                <Citation>Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109.</Citation>
            </Reference>
            <Reference>
                <Citation>Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48:1161-1168.</Citation>
            </Reference>
            <Reference>
                <Citation>Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2000.</Citation>
            </Reference>
            <Reference>
                <Citation>McCawley N, Clancy C, O'Neill BDP, Deasy J, McNamara DA, Burke JP. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Dis Colon Rectum. 2016;59:1200-1208.</Citation>
            </Reference>
            <Reference>
                <Citation>Debunne H, Ceelen W. Mucinous differentiation in colorectal cancer: molecular, histological and clinical aspects. Acta Chir Belg. 2013;113:385-390.</Citation>
            </Reference>
            <Reference>
                <Citation>Song G, Deng G, Bell I, Kakar S, Sleisenger M, Kim Y. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005;26:745-750.</Citation>
            </Reference>
            <Reference>
                <Citation>Albanese I, Rinaudo C, Alberti M, et al. ras and myc analysis in primary and metastatic colorectal carcinomas. Int J Oncol. 1997;10:293-300.</Citation>
            </Reference>
            <Reference>
                <Citation>Bazan V. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002;13:1438-1446.</Citation>
            </Reference>
            <Reference>
                <Citation>Liddell C, Droy-DuprÃ© L, MÃ©tairie S, et al. Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach. Mod Pathol. 2017;30:1177-1189.</Citation>
            </Reference>
            <Reference>
                <Citation>Jang MH, Kim S, Hwang DY, et al. BRAF-mutated colorectal cancer exhibits distinct clinicopathological features from wild-type BRAF-expressing cancer independent of the microsatellite instability status. J Korean Med Sci. 2017;32:38-46.</Citation>
            </Reference>
            <Reference>
                <Citation>Andrici J, Farzin M, Sioson L, et al. Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer. Mod Pathol. 2016;29:266-274.</Citation>
            </Reference>
            <Reference>
                <Citation>Inamura K, Yamauchi M, Nishihara R, et al. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol. 2015;22:1226-1235.</Citation>
            </Reference>
            <Reference>
                <Citation>Reynolds IS, Furney SJ, Kay EW, McNamara DA, Prehn JHM, Burke JP. Meta-analysis of the molecular associations of mucinous colorectal cancer. Br J Surg. 2019;106:682-691.</Citation>
            </Reference>
            <Reference>
                <Citation>Luzzatto L. Somatic mutations in cancer development. Environ Health. 2011;10(suppl 1):S12.</Citation>
            </Reference>
            <Reference>
                <Citation>Stanley R, Hamilton LAA. World Health Organization Classification of Tumours-Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000.</Citation>
            </Reference>
            <Reference>
                <Citation>Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173:321.e10-337.e10.</Citation>
            </Reference>
            <Reference>
                <Citation>Wang C, Liang C. MSIpred: a python package for tumor microsatellite instability classification from tumor mutation annotation data using a support vector machine. Sci Rep. 2018;8. 17546.</Citation>
            </Reference>
            <Reference>
                <Citation>Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747-1756.</Citation>
            </Reference>
            <Reference>
                <Citation>Puca L, Chastagner P, Meas-Yedid V, Israel A, Brou C. A-arrestin 1 (ARRDC1) and Î²-arrestins cooperate to mediate Notch degradation in mammals. J Cell Sci. 2013;126:4457-4468.</Citation>
            </Reference>
            <Reference>
                <Citation>Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol. 2010;30:908-921.</Citation>
            </Reference>
            <Reference>
                <Citation>Sarbassov DD. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101.</Citation>
            </Reference>
            <Reference>
                <Citation>Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302.</Citation>
            </Reference>
            <Reference>
                <Citation>Csukasi F, Duran I, Barad M, et al. The PTH/PTHrP-SIK3 pathway affects skeletogenesis through altered mTOR signaling. Sci Transl Med. 2018;10. eaat9356.</Citation>
            </Reference>
            <Reference>
                <Citation>Wang JQ, Chen JH, Chen YC, et al. Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific domains. PLoS One. 2013;8:e65586.</Citation>
            </Reference>
            <Reference>
                <Citation>Kulkarni SV, Gish G, van der Geer P, Henkemeyer M, Pawson T. Role of p120 Ras-GAP in directed cell movement. J Cell Biol. 2000;149:457-470.</Citation>
            </Reference>
            <Reference>
                <Citation>Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002;38:867-871.</Citation>
            </Reference>
            <Reference>
                <Citation>Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000;18:1967-1979.</Citation>
            </Reference>
            <Reference>
                <Citation>Hugen N, Simons M, HaliloviÄ A, et al. The molecular background of mucinous carcinoma beyond MUC2. J Pathol Clin Res. 2015;1:3-17.</Citation>
            </Reference>
            <Reference>
                <Citation>Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-1422.</Citation>
            </Reference>
            <Reference>
                <Citation>Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol. 2017;8:387-404.</Citation>
            </Reference>
            <Reference>
                <Citation>Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182-1191.</Citation>
            </Reference>
            <Reference>
                <Citation>Chouhan H, Sammour T, Thomas ML, Moore JW. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. J Surg Oncol. 2018;118:1311-1317.</Citation>
            </Reference>
            <Reference>
                <Citation>Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol. 2019;37:1460-1469.</Citation>
            </Reference>
            <Reference>
                <Citation>Ciombor KK, Goldberg RM. Hypermutated tumors and immune checkpoint inhibition. Drugs. 2018;78:155-162.</Citation>
            </Reference>
            <Reference>
                <Citation>Nebot-Bral L, Brandao D, Verlingue L, et al. Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur J Cancer. 2017;84:290-303.</Citation>
            </Reference>
            <Reference>
                <Citation>Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.</Citation>
            </Reference>
            <Reference>
                <Citation>Carethers JM. Microsatellite instability pathway and EMAST in colorectal cancer. Curr Colorectal Cancer Rep. 2017;13:73-80.</Citation>
            </Reference>
            <Reference>
                <Citation>Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JPJ. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-8686.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704871</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6379-6387</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13851</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">In the present retrospective study, we assessed the molecular profile and clinicopathological correlations of Greek colorectal carcinoma (CRC) patients.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Data from 157 CRC patients were collected. High Resolution Melting Analysis and Pyrosequencing/Sanger sequencing were applied to identify KRAS, BRAF, NRAS mutations and microsatellite instability (MSI) status. Immunohistochemistry was performed to characterize the associated Mismatch Repair Protein loss. Statistical calculations were performed using the statistical package SPSS v21.0.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">KRAS mutations were detected in 39.3% of cases, BRAF in 10.9% and NRAS in 4.9%. MSI status was recognized in 11.5% of CRC patients and was associated with right colon tumors. MSI phenotype was inversely correlated with stage, N status and KRAS mutations and positively correlated with BRAF mutations.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MSI positive CRCs in the Greek population are more often right-sided, free of metastasis, KRAS wild type and BRAF mutated. Providing more detailed clinicopathological and molecular data for specific populations will enable better clinical management and individualized therapy in the future.</AbstractText>
                <CopyrightInformation>CopyrightÂ© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Katafygiotis</LastName>
                    <ForeName>Patroklos</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece patlamkat@yahoo.gr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakellariou</LastName>
                    <ForeName>Stratigoula</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chatziandreou</LastName>
                    <ForeName>Ilenia</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giannopoulou</LastName>
                    <ForeName>Ioanna</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thymara</LastName>
                    <ForeName>Irene</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saetta</LastName>
                    <ForeName>Angelica A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korkolopoulou</LastName>
                    <ForeName>Penelope</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C117307">KRAS protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="C579846">NRAS protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012811" MajorTopicYN="N">Sigmoid Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRAF mutations</Keyword>
            <Keyword MajorTopicYN="N">Colorectal Cancer</Keyword>
            <Keyword MajorTopicYN="N">KRAS</Keyword>
            <Keyword MajorTopicYN="N">MSI</Keyword>
            <Keyword MajorTopicYN="N">NRAS</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704871</ArticleId>
            <ArticleId IdType="pii">39/11/6379</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13851</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31703812</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-6859</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>155</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gynecologic oncology</Title>
                <ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.</ArticleTitle>
            <Pagination>
                <MedlinePgn>473-482</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0090-8258(19)31561-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2019.10.004</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE">We analyzed comprehensive genomic sequencing results from paired ovarian cancer samples to identify changes in mutational events over time.</AbstractText>
                <AbstractText Label="METHODS">DNA from paired FFPE tumor samples from 50 ovarian cancer patients in the Clearity Foundation Data Repository was analyzed for genomic mutations (GM), copy number alterations (CNA), microsatellite status (MS), tumor mutation burden (TMB), and loss of heterozygosity (LOH) by hybrid-capture, next-generation sequencing of up to 315 genes. Genomic profiles were compared between samples from the same patient. Poor quality results excluded 6 pairs from all analyses and 9 from CNA or LOH.</AbstractText>
                <AbstractText Label="RESULTS">Forty-four patients with predominantly advanced stage disease (34, 77%) and serous histology (31, 70%) received a median of 3 intervening treatment regimens (range 1-13). Analysis of 22 primary and recurrent sample pairs and 22 recurrent tumor pairs detected a median of 2 GM (range 0-5) and 1 CNA (range 0-6)/sample. TMB, MS, and LOH results were mostly concordant across paired samples. GM were consistent across most pairs [32/44 (73%) concordant], while CNA concordance was less [18/35 (51%)]. No changes were detected in therapeutically relevant GM, but 23% of patients had GM or CNA in the second sample that affect clinical trial eligibility.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Paired ovarian cancer samples demonstrate stable genomic alterations across time. However, discordance was observed for some genes used as eligibility criteria for molecularly targeted clinical trials. Repeat tumor testing may be useful in cases where eligibility for such trials is deemed important after consideration of testing costs and potential clinical benefit.</AbstractText>
                <CopyrightInformation>Copyright Â© 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fehniger</LastName>
                    <ForeName>Julia E</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berger</LastName>
                    <ForeName>Amnon A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Juckett</LastName>
                    <ForeName>Luke</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Foundation Medicine, Inc, Cambridge, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elvin</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Foundation Medicine, Inc, Cambridge, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levine</LastName>
                    <ForeName>Douglas A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zajchowski</LastName>
                    <ForeName>Deborah A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Clearity Foundation, San Diego, CA, USA. Electronic address: dzajchowski@clearityfoundation.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016087</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gynecol Oncol</MedlineTA>
            <NlmUniqueID>0365304</NlmUniqueID>
            <ISSNLinking>0090-8258</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019656" MajorTopicYN="N">Loss of Heterozygosity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Copy number alterations</Keyword>
            <Keyword MajorTopicYN="Y">Mutation</Keyword>
            <Keyword MajorTopicYN="Y">Next generation sequencing</Keyword>
            <Keyword MajorTopicYN="Y">Ovarian cancer</Keyword>
            <Keyword MajorTopicYN="Y">Precision medicine</Keyword>
            <Keyword MajorTopicYN="Y">Recurrence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31703812</ArticleId>
            <ArticleId IdType="pii">S0090-8258(19)31561-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ygyno.2019.10.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31701729</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1421-9778</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>53</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>
                <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical Evidence on the Interaction Between MLK4, KRAS and Microsatellite Instability to Determine the Prognosis of Early-Stage Colorectal Carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>820-831</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.33594/000000175</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">MLK4 (KIAA1804) is the second most frequently mutated kinase in microsatellite stable (MSS) colorectal carcinomas (CRC). This molecule is known to regulate different physiological cellular processes, including cell cycle, senescence and apoptosis, and mechanistic evidence has been provided that MLK4 plays a role in carcinogenesis. However, whether this kinase exerts a tumor suppressive role or an oncogenic function is still an object of debate. This study aims to elucidate the role of MLK4 in the pathogenesis of CRC by investigating human tumor specimens.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This study assessed MLK4 expression levels by immunohistochemistry in surgical tumor samples from 204 early-stage CRC patients and their correlation with various clinical-pathological features and patients' outcomes. In addition, MLK4 mRNA transcription was analysed in an independent cohort of 786 colon cancer samples.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Loss of MLK4 staining was associated with poor overall (OS) and progression free survival (PFS) in CRC patients during a univariate analysis (OS:101 vs 164 months, p=0.0002; PFS:85 vs 125 months, p=0.0001), as well as in multivariate analysis (OS:HR=1.70; p=0.001; PFS:HR=1,61; p=0.001). This was confirmed by analysis of MLK4 mRNA in the second independent cohort. A subgroup analysis according to KRAS mutation status showed that MLK4 staining was associated with better OS and PFS in KRAS mutated cases (HR=2.77; p=0.0001 and HR=2.31; p=0.0003, respectively) and microsatellite stable tumors (HR=1.87; p=0.002 and HR=1.06; p=0.006) but not in KRAS wildtype and microsatellite unstable tumors.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">By providing the first report from clinical specimens on the prognostic significance of MLK4, we define an oncogenic loss-of-function of this kinase and suggest a possible role in the interaction with KRAS signaling in determining an aggressive phenotype of CRC. These findings warrant the further investigation of MLK4 in wider cohorts and various clinical settings.</AbstractText>
                <CopyrightInformation>Â© Copyright by the Author(s). Published by Cell Physiol Biochem Press.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brandl</LastName>
                    <ForeName>Lydia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horst</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, CharitÃ© -UniversitÃ¤tsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), partner site Munich, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>GrÃ¼newald</LastName>
                    <ForeName>Thomas G P</ForeName>
                    <Initials>TGP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), partner site Munich, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mayerle</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine 2, University Hospital Grosshadern, University of Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sendelhofert</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neumann</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirchner</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), partner site Munich, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Toni</LastName>
                    <ForeName>Enrico N</ForeName>
                    <Initials>EN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine 2, University Hospital Grosshadern, University of Munich, Munich, Germany, enrico.detoni@med.uni-muenchen.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DKH-111886, DKH-70112257</GrantID>
                    <Agency>German Cancer Aid</Agency>
                    <Country>Germany</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cell Physiol Biochem</MedlineTA>
            <NlmUniqueID>9113221</NlmUniqueID>
            <ISSNLinking>1015-8987</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.11.25</RegistryNumber>
                <NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.25</RegistryNumber>
                <NameOfSubstance UI="C582627">MAP3K21 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020930" MajorTopicYN="N">MAP Kinase Kinase Kinases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MLK4; KRAS; MSI; MSS; Colorectal carcinomas; Prognosis</Keyword>
        </KeywordList>
        <CoiStatement>No conflicts of interest exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31701729</ArticleId>
            <ArticleId IdType="doi">10.33594/000000175</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31699342</PMID>
        <DateCompleted>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>03</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-135X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>847</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Mutation research</Title>
                <ISOAbbreviation>Mutat. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Horizon scanning for novel and emerging in vitro mammalian cell mutagenicity test systems.</ArticleTitle>
            <Pagination>
                <MedlinePgn>403024</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1383-5718(18)30439-X</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mrgentox.2019.02.005</ELocationID>
            <Abstract>
                <AbstractText>The induction of gene mutation within a DNA sequence can result in an adverse impact, altering or preventing gene function. Therefore, in vitro evaluation of mutagenicity is an essential component of the toxicological screening process. A variety of mutagen screening tools are routinely used in genetic toxicology, which are based on selected reporter genes. These assays are however typically labour intensive and impractical for high throughput screening. Considering this, the IWGT (International Workshops on Genotoxicity Testing) sub-group on Novel &amp; Emerging in vitro Mammalian Cell Mutagenicity Test Systems undertook a literature search to identify new approaches for mutation detection. This review therefore focused on identifying new approaches for mutation detection that have the potential for use as a future genotoxicity screening tool. A comprehensive literature review identified genome-wide loss-of-function screening tools, next generation sequencing (NGS) mutation characterisation and fluorescence-based mutation detection methods as having significant promise as an emerging in vitro mammalian cell mutagenicity test system. Each of the technologies considered was assessed for its capacity to report on a wide array of heritable mutagenic changes, necessary to cover the full spectrum of genetic events imparted by substances with a broad range of modes of action. Of the technologies evaluated, NGS techniques exhibited the greatest advantages for use in a genotoxicity testing setting. However, it is important to note that the emerging techniques identified could not facilitate routine mutagenicity testing in their current format and require substantial additional optimisation and tailoring before they could be utilised as an in vitro mammalian cell mutagenicity test system. Additionally, new mammalian cell mutation test systems must be able to accurately and reliably detect and quantify rare events; hence any new system would require careful validation. Nevertheless, with further development emerging technologies such as NGS could become important in establishing more predictive and high-throughput regulatory hazard screening tools of the future.</AbstractText>
                <CopyrightInformation>Copyright Â© 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Evans</LastName>
                    <ForeName>Stephen J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, Wales, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gollapudi</LastName>
                    <ForeName>Bhaskar</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Exponent, Inc., 1800 Diagonal Road, Suite 500, Alexandria, VA 22314, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moore</LastName>
                    <ForeName>Martha M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ramboll, 124 West Capitol Avenue, Suite 1605, Little Rock, AR 72201, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doak</LastName>
                    <ForeName>Shareen H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>In Vitro Toxicology Group, Institute of Life Science, Swansea University Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, Wales, UK. Electronic address: s.h.doak@swansea.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016446">Consensus Development Conference</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mutat Res</MedlineTA>
            <NlmUniqueID>0400763</NlmUniqueID>
            <ISSNLinking>0027-5107</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004251">DNA Transposable Elements</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-49-2</RegistryNumber>
                <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004251" MajorTopicYN="N">DNA Transposable Elements</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006238" MajorTopicYN="N">Haploidy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009152" MajorTopicYN="N">Mutagenicity Tests</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012641" MajorTopicYN="N">Selection, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Gene mutation</Keyword>
            <Keyword MajorTopicYN="Y">Haploid cells</Keyword>
            <Keyword MajorTopicYN="Y">Mutation reporter screen</Keyword>
            <Keyword MajorTopicYN="Y">Next generation sequencing</Keyword>
            <Keyword MajorTopicYN="Y">Trinucleotide repeat instability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>3</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31699342</ArticleId>
            <ArticleId IdType="pii">S1383-5718(18)30439-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.mrgentox.2019.02.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

